Financière de Tubize SA Ex-dividend date
What is the Ex-dividend date of Financière de Tubize SA?
The Ex-dividend date of Financière de Tubize SA is N/A
What is the definition of Ex-dividend date?
Ex-dividend date is the cut-off date before which the payment of dividends after a sale belongs to the new owner instead of the seller.
The ex-dividend date or reinvestment date is an investment term involving the timing of payment of dividends on stocks of corporations, income trusts, and other financial holdings. If a sale is before this date, the dividend belongs to the new owner; if on or after the date, the seller is entitled to the dividend. If a stock is purchased on its ex-dividend date or after, the buyer will not receive the next dividend payment. Instead, the seller gets the dividend. If a stock is purchased before the ex-dividend date, the buyer gets the dividend.
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.